Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.

Abstract: Described herein is an aqueous composition including particles coated with at least one non-amphoteric, quaternizable polymer which is water soluble at 20° C., and at least one dispersing component, where the dispersing component includes a dispersing agent selected from an amphiphilic graft polymer based on water-soluble polyalkylene oxides (A) as a graft base and side chains formed by polymerization of a vinyl ester component (B), the polymer having an average of ?1 graft site per 50 alkylene oxide units and a mean molar mass Mw of from 3000 to 100 000.

Abstract: Skin tightening compositions for application to the skin for providing an instantaneous and dramatic improvement to the appearance of skin. The skin tightening compositions typically include about 5 to about 45 wt. % or more of one or more hydrophobic film-forming polymers comprising acrylates/stearyl methacrylate copolymer; about 0.5 to about 20 wt. % of a mineral thickening agent; about 1 to about 15 wt. % of a silicone elastomer; and about 30 to about 85 wt. % of a volatile hydrocarbon oil, wherein all percentages by weight are based on the total weight of the skin tightening composition. Additionally, the skin tightening composition may have a weight ratio of the total amount of hydrophobic film-forming polymers to the total amount of mineral thickening agent is 1:1 to 10:1 and a weight ratio of the total amount of silicone elastomer to the total amount of mineral thickening agent is 1:2 to 8:1.

Abstract: A dispersion containing a dispersed phase comprising drops and a continuous aqueous phase, preferably in the form of gel, in which the drops comprise a fatty phase containing at least one gelling agent, and in which the fatty phase comprises at least one non-volatile hydrocarbon oil H1 containing more than 90%, and preferably more than 95%, fatty acids having at least 18 carbon atoms and preferably at least 20 carbon atoms.

Abstract: A polyurethane elastomeric rubber composition containing a bio-based polyol cross-linked with a bio-based isocyanate using a urethanation catalyst such as a bismuth catalyst in the presence of a cosmetic emollient is disclosed. The cross-linked polyurethane elastomer rubber is in further aspect of the invention included in a gel after being milled in the presence of a bio-based emollient or mixture of bio-based emollients. The polyurethane elastomeric gel has good compatibility with cosmetic and natural oils and can be used as a gelling agent for these oils among other desirable cosmetic formulary roles.

Abstract: A cellulose-containing article for treating an area of skin, wherein the article comprises BNC in an amount of at least 1% by weight and at most 15% by weight, comprises fluid in an amount of at least 85% by weight and at most 99% by weight, has an average thickness of at least 0.5 mm and at most 8 mm, wherein the BNC is of microbial origin.

Abstract: Methods for quality control and optimizing the formation and characterization of micelles, vesicles or other aggregates are described herein. Pharmaceutically relevant peptides may be modified to form glycopeptide surfactants which form micelles or other aggregates with another surfactant. Glycopeptide and glycolipid surfactants can aggregate to form particles that enhance drug delivery. The glycopeptide surfactants may be drugs or pro-drugs which are delivered via the micelles or other aggregated structures.

Abstract: Film-forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film-forming polymer, an amine-rich adhesion promoter, and a volatile solvent. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing.

Abstract: The present disclosure relates to multi-functional anti-microbial polymers comprising a first monomer having a polymerizable cyclic aromatic moiety which forms part of the backbone of the polymer and a second monomer having an ethylenically unsaturated monomer having a double or triple bond and a quaternary ammonium or quaternary phosphonium moiety.

Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.

Abstract: The present invention relates to a use of an agarobiose or agarooligosaccharides having anticariogenic activity. More specifically, a lower concentration of agarobiose or agarooligosaccharides than the concentration of xylitol suppresses the growth of Streptococcus mutans and suppresses acid production, and thus can be used for anti-cariogenic purposes.

Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.

Abstract: A process for the preparation of oral delayed release solid formulations and the formulations obtainable from said process are now described. Said process comprises the following steps: a) melting at least one lipid; b) spraying said at least one melted lipid on at least one active ingredient in the form of a moving powder; c) cooling the resulting mixture; d) optional granulation of the mixture; e) optional compression of the mixture.

Abstract: An oral care composition and methods for preparing the oral care composition are disclosed. The oral care composition may include a carrier and a structure-building agent. The carrier may be present in an amount of from about 0.01 wt % to about 99 wt %. The structure-building agent may include a polyvinyl capralactam-polyvinyl acetate-polyethylene glycol graft copolymers (PCA-PVA-PEG), and may be present in an amount of from about 0.01 wt % to about 60 wt %, based on a total weight of the oral care composition.

Abstract: The present invention relates to a composition for dyeing and/or bleaching human keratin fibers, such as the hair, comprising: a) at 0.15% of at least one neutralized fatty acid, please confirm the minimum amount of fatty acid salt in the ready to use composition b) at least one non ionic surfactant, c) at least one non associative polymer chosen from amphoteric polymers, cationic polymers and mixture thereof, d) at least 10% by weight relative to the total weight of the composition, of at least one fatty substance other than fatty acids, e) at least one oxidizing agent, and f) optionally at least one oxidation dye precursor and/or at least one direct dye. The invention also relates to a method for treating human keratin fibres using this composition.

Abstract: Disclosed are dendritic anionic lipids which are compounds of Formula (I): wherein R and R1 are non-polar groups, L is a linking moiety, and Dm is a dendritic moiety of m generations, each as defined herein. These dendritic anionic lipids are useful for delivery and expression of m RNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

Abstract: An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

Abstract: The invention relates to a process for straightening keratin fibres, comprising: (i) a step in which a straightening composition containing at least two denaturing agents is applied to the keratin fibres, (ii) a step in which the temperature of the keratin fibres is raised, using a heating means, to a temperature of between 110 and 250° C.

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.